Sepsis is a life-threatening condition caused by the body’s overreaction to an infection. It affects more than 30 million people around the world each year and results in 6 million deaths. Identifying and treating the condition as early as possible can greatly increase a patient’s likelihood of survival.*
*Kim HI, Park S. Sepsis: Early recognition and optimized treatment. Tuberc Respir Dis (Seoul). 2019;82(1):6-14. doi:10.4046/trd.2018.0041.
Fast, accurate testing to help save lives
VITROS B•R•A•H•M•S PCT (Procalcitonin) assay helps you make confident antibiotic treatment decisions.
Long calibrations and fast turnaround time allow you to treat patients faster.
Our assays were built to consistently produce accurate results – the first time.
Adding VITROS Interleukin-6 (IL-6) assay* to your lab's menu can enable accurate treatment of your most sensitive patients.
*Not available in all countries. Contact your QuidelOrtho representative for more information.
VITROS® B•R•A•H•M•S PCT (Procalcitonin) Assay provides therapeutic guidance for antibiotic treatment
This assay offers excellent analytical correlation and clinical concordance to the B•R•A•H•M•S clinical decision points.
- Helps provide therapeutic guidance for starting and safely stopping antibiotic treatment in support of your institution’s antibiotic stewardship initiatives1,2
- Enables more requests to be fulfilled from difficult draws with a small sample volume of 30 μL
- Provides reliable results through quantification of endogenous hemolysis, icterus and turbidity with MicroSensor technology
- Maximizes efficiency with long calibration intervals of 56 days
Learn more about our VITROS portfolio of testing solutions.
*B•R•A•H•M•S PCT is a trademark of Thermo Fisher Scientific. All other trademarks are the property of QuidelOrtho Corporation.
1. Ortho Clinical Diagnostics (2020). VITROS Immunodiagnostics Products B•R•A•H•M•S PCT Reagent Pack and Calibrators Instructions For Use. Pub. No. GEM1370_XUS_EN version 2.0.
2. Foster M, Vealey J, Barba M. Best Practices in Laboratory Operations – Advances in Acquisition Decision Criteria. Business Briefing Report: Labtech 2004.
VITROS® IL-6 Reagent Pack* helps provide better patient care
Confidently and accurately treat critically ill patients by adding interleukin-6 (IL-6) assay to your lab’s menu to enable the detection of inflammatory diseases in your most sensitive patients, so clinicians can treat patients sooner.
- Delivers a 7.5-hour time advantage over C-reactive protein (CRP) to reach diagnostic cutoff for both bacterial and viral infections1
- Provides standardized results you can trust across the VITROS systems family of instruments with excellent analytical performance
- Offers a cost-effective diagnostic complement to CRP and PCT with utility in your most critically ill patients
Learn more about our acute care testing solutions.
*Not available in all countries. Contact your local QuidelOrtho representative for more information.
1. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396-402. doi:10.1164/ajrccm.164.3.2009052
IL-6
VITROS® 7600 Integrated System
VITROS® 5600 Integrated System
VITROS® 3600 Immunodiagnostic System
VITROS® ECI/ECiQ Immunodiagnostic System
Procalcitonin
VITROS® 7600 Integrated System
VITROS® 5600 Integrated System
VITROS® 3600 Immunodiagnostic System
VITROS® ECI/ECiQ Immunodiagnostic System
The VITROS® System
-
VITROS® 7600 Integrated System
-
VITROS® 5600 Integrated System
-
VITROS® 3600 Immunodiagnostic System
-
VITROS® ECI/ECiQ Immunodiagnostic System
-
VITROS® 4600 Integrated System
-
VITROS® XT 3400 Integrated System
